Amrubicin at a dose of 45mg/m2 with pegylated granulocyte-colony stimulating factor support in patients with previously treated small-cell lung cancer - A prospective observational study
- Conditions
- small-cell lung cancer
- Registration Number
- JPRN-UMIN000034657
- Lead Sponsor
- Tottori University Hospital Division of Medical Ontology and Molecular Respirology Tottori University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 17
Not provided
1.Transfusion and administration of hematopoietic factor preparations within 14 days before registration. 2.Serious renal dysfunction, or urine protein 2+ or higher in tests registered within 14 days. 3.Serious drug allergy. 4.Duplicate cancer of active. 5.Infections requiring systemic treatment. 6.Fever above 38 degrees Celsius. 7.Significant electrocardiogram abnormality or clinically problematic heart disease. 8.Severe lung disease. 9.Fresh bleeding from the gastrointestinal tract, intestinal palsy, intestinal obstruction or peptic ulcer. 10.Pleural effusion, ascites and pericardial effusion requiring removal of body cavity fluid by drain. 11.Defective thromboembolism. 12.Symptomatic brain metastasis. 13.Serious psychiatric disorders, central nervous disorders or cerebrovascular disorders. 14.Control poor hypertension or diabetes. 15.Severe bone marrow suppression. 16.Pregnant women, lactating women or women with a positive pregnancy test. A woman without intention to contraception. A woman wishing to become pregnant or breastfeeding. A man who is willing to conceive. 17.Cases the attending physician determines that inappropriate to participate in the test.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Response Rate
- Secondary Outcome Measures
Name Time Method